Euroapi SAS
PAR:EAPI
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (3.9), the stock would be worth €9.91 (638% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | €1.34 |
0%
|
| 3-Year Average | 3.9 | €9.91 |
+638%
|
| 5-Year Average | 4 | €10.1 |
+652%
|
| Industry Average | 6.5 | €16.6 |
+1 137%
|
| Country Average | 7.3 | €18.56 |
+1 283%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€76.3m
|
/ |
Jan 2026
€144.2m
|
= |
|
|
€76.3m
|
/ |
Dec 2026
€84.3m
|
= |
|
|
€76.3m
|
/ |
Dec 2027
€104.7m
|
= |
|
|
€76.3m
|
/ |
Dec 2028
€140.7m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
E
|
Euroapi SAS
PAR:EAPI
|
127.8m EUR | 0.5 | -0.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD | 30.5 | 45.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 15 | 21.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF | 12.4 | 21 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF | 13.5 | 21.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 16.3 | 29.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD | 9.8 | 15.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 344.9 | -74.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 7.2 | 17.2 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 5.3 |
| Median | 7.3 |
| 70th Percentile | 11.7 |
| Max | 1 862.3 |
Other Multiples
Euroapi SAS
Glance View
EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,342 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
